.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,716,261

« Back to Dashboard

Details for Patent: 8,716,261

Title:Maintenance of platelet inhibition during antiplatelet therapy
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Inventor(s): Ruderman Chen; Lisa (Rye, NY), Skerjanec; Simona (Basel, CH), Bell; Dawn (Morristown, NJ), Prats; Jayne (Carlisle, MA), Todd; Meredith (Hoboken, NJ)
Assignee: The Medicines Company (Parsippany, NJ)
Filing Date:Jul 30, 2013
Application Number:13/954,821
Claims:1. A method of maintaining platelet P2Y.sub.12 receptor inhibition in a patient in need thereof who is being treated with a long-acting irreversible P2Y.sub.12 inhibitor and is in need of an invasive procedure, the method comprising: (a) discontinuing the treatment with the long-acting irreversible P2Y.sub.12 inhibitor; (b) administering intravenously a 0.75 .mu.g/kg/min continuous infusion of cangrelor; and (c) discontinuing the administration of cangrelor at least about one hour prior to administration of anesthesia for the invasive procedure.

2. The method of claim 1, wherein prior to the administration of cangrelor the patient is at an increased risk for thrombotic events when treatment with the long-acting irreversible P2Y.sub.12 inhibitor is discontinued.

3. The method of claim 1, wherein the invasive procedure is a surgical procedure.

4. The method of claim 1, wherein the cangrelor is administered as quickly as possible following the discontinuation of treatment with the long-acting irreversible P2Y.sub.12 inhibitor.

5. The method of claim 1, wherein the long-acting irreversible P2Y.sub.12 inhibitor is in an oral dosage form.

6. The method of claim 5, wherein the long-acting irreversible P2Y.sub.12 inhibitor is a thienopyridine.

7. The method of claim 6, wherein the cangrelor is administered within about 5 days of the discontinuation of treatment with the thienopyridine.

8. The method of claim 6, wherein the administration of cangrelor is discontinued after no longer than about 7 days from initiation of the administration of cangrelor.

9. The method of claim 1, wherein the patient has acute coronary syndrome (ACS).

10. The method of claim 1, wherein the patient previously received a stent.

11. The method of claim 6, wherein the thienopyridine is selected from a group consisting of clopidogrel, ticlopidine, prasugrel, and a combination thereof.

12. A method of maintaining platelet P2Y.sub.12 receptor inhibition in a patient in need thereof who has acute coronary syndrome (ACS), is being treated with a long-acting irreversible P2Y.sub.12 inhibitor, and is at an increased risk for thrombotic events when said treatment is discontinued due to the need for a surgical procedure, the method comprising: (a) discontinuing the treatment with the long-acting irreversible P2Y.sub.12 inhibitor; (b) administering intravenously a 0.75 .mu.g/kg/min continuous infusion of cangrelor; and (c) discontinuing the administration of cangrelor at least about one hour prior to administration of anesthesia for the surgical procedure.

13. The method of claim 12, wherein the cangrelor is administered as quickly as possible following the discontinuation of treatment with the long-acting irreversible P2Y.sub.12 inhibitor.

14. The method of claim 12, wherein the long-acting irreversible P2Y.sub.12 inhibitor is in an oral dosage form.

15. The method of claim 14, wherein the long-acting irreversible P2Y.sub.12 inhibitor is a thienopyridine.

16. The method of claim 15, wherein the cangrelor is administered within about 5 days of the discontinuation of treatment with the thienopyridine.

17. The method of claim 15, wherein the administration of cangrelor is discontinued after no longer than about 7 days from initiation of the administration of cangrelor.

18. The method of claim 15, wherein the thienopyridine is selected from a group consisting of clopidogrel, ticlopidine, prasugrel, and a combination thereof.

19. A method of maintaining platelet P2Y.sub.12 receptor inhibition in a patient in need thereof who previously received a stent, is being treated with a long-acting irreversible P2Y.sub.12 inhibitor, and is at an increased risk for thrombotic events when said treatment is discontinued due to the need for a surgical procedure, the method comprising: (a) discontinuing the treatment with the long-acting irreversible P2Y.sub.12 inhibitor; (b) administering intravenously a 0.75 .mu.g/kg/min continuous infusion comprising cangrelor; and (c) discontinuing the administration of cangrelor at least about one hour prior to administration of anesthesia for the surgical procedure.

20. The method of claim 19, wherein the cangrelor is administered as quickly as possible following the discontinuation of treatment with the long-acting irreversible P2Y.sub.12 inhibitor.

21. The method of claim 19, wherein the long-acting irreversible P2Y.sub.12 inhibitor is in an oral dosage form.

22. The method of claim 21, wherein the long-lasting irreversible P2Y.sub.12 inhibitor is a thienopyridine.

23. The method of claim 22, wherein the cangrelor is administered within about 5 days of the discontinuation of treatment with the thienopyridine.

24. The method of claim 22, wherein administration of the cangrelor is discontinued after no longer than about 7 days from initiation of administration of the cangrelor.

25. The method of claim 22, wherein the thienopyridine is selected from a group consisting of clopidogrel, ticlopidine, prasugrel, and a combination thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc